Literature DB >> 22744936

Shrinkage estimation in two-stage adaptive designs with midtrial treatment selection.

Máximo Carreras1, Werner Brannath.   

Abstract

We consider the problem of estimation in adaptive two-stage designs with selection of a single treatment arm at an interim analysis. It is well known that the standard maximum-likelihood estimator of the selected treatment is biased. We prove that selection bias of the maximum-likelihood estimator is maximal when all treatment effects are equal and the most-promising treatment is selected. Furthermore, we consider shrinkage estimation as a solution for the selection bias problem. We thereby extend previous work of Hwang on Lindley's estimator for single-stage multi-armed trials with four or more treatments and post-trial treatment selection. Following Hwang's ideas, we show that a simple two-stage version of Lindley's estimator has uniformly smaller Bayes risk than the maximum-likelihood estimator when assuming an empirical Bayesian framework with independent normal priors for the group means. For designs that start with two or three treatment groups, we suggest using a two-stage version of the common estimator of the best linear unbiased predicator of the corresponding random effects model. We show by an extensive simulation study that the shrinkage estimators perform well compared with maximum-likelihood and previously suggested bias-adjusted estimators in terms of selection bias and mean squared error.
Copyright © 2012 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 22744936     DOI: 10.1002/sim.5463

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  15 in total

1.  Point and interval estimation in two-stage adaptive designs with time to event data and biomarker-driven subpopulation selection.

Authors:  Peter K Kimani; Susan Todd; Lindsay A Renfro; Ekkehard Glimm; Josephine N Khan; John A Kairalla; Nigel Stallard
Journal:  Stat Med       Date:  2020-05-03       Impact factor: 2.373

2.  Correcting for bias in the selection and validation of informative diagnostic tests.

Authors:  David S Robertson; A Toby Prevost; Jack Bowden
Journal:  Stat Med       Date:  2015-02-01       Impact factor: 2.373

3.  Conditionally unbiased estimation in phase II/III clinical trials with early stopping for futility.

Authors:  Peter K Kimani; Susan Todd; Nigel Stallard
Journal:  Stat Med       Date:  2013-02-15       Impact factor: 2.373

4.  Conditionally unbiased and near unbiased estimation of the selected treatment mean for multistage drop-the-losers trials.

Authors:  Jack Bowden; Ekkehard Glimm
Journal:  Biom J       Date:  2013-12-18       Impact factor: 2.207

5.  Estimation after subpopulation selection in adaptive seamless trials.

Authors:  Peter K Kimani; Susan Todd; Nigel Stallard
Journal:  Stat Med       Date:  2015-04-22       Impact factor: 2.373

6.  Unbiased estimation in seamless phase II/III trials with unequal treatment effect variances and hypothesis-driven selection rules.

Authors:  David S Robertson; A Toby Prevost; Jack Bowden
Journal:  Stat Med       Date:  2016-04-21       Impact factor: 2.373

7.  Estimation in multi-arm two-stage trials with treatment selection and time-to-event endpoint.

Authors:  Matthias Brückner; Andrew Titman; Thomas Jaki
Journal:  Stat Med       Date:  2017-06-13       Impact factor: 2.373

8.  Empirical Bayes estimation of the selected treatment mean for two-stage drop-the-loser trials: a meta-analytic approach.

Authors:  Jack Bowden; Werner Brannath; Ekkehard Glimm
Journal:  Stat Med       Date:  2013-07-22       Impact factor: 2.373

9.  Precision of maximum likelihood estimation in adaptive designs.

Authors:  Alexandra Christine Graf; Georg Gutjahr; Werner Brannath
Journal:  Stat Med       Date:  2015-10-12       Impact factor: 2.373

10.  Generalizing boundaries for triangular designs, and efficacy estimation at extended follow-ups.

Authors:  Annabel Allison; Tansy Edwards; Raymond Omollo; Fabiana Alves; Dominic Magirr; Neal D E Alexander
Journal:  Trials       Date:  2015-11-16       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.